The linked FDA records link Fidelity BioPharma Co. to a single premarket notification, K260396, received February 6, 2026, and decided September 6, 2026 as substantially equivalent. The device is described as a KCS rTMS Therapy System (Transcranial Magnetic Stimulator) with model names MetaStim 100 and MetaStim 100A. The clearance type is Traditional, the third-party review flag is N, and the submission includes a summary rather than only a statement. The applicant name appears as the legal applicant on the FDA decision letter, which is addressed in care of a manager at Guangzhou Medical Consultant, Ltd. in Guangzhou, China. [1][2][9]
Documented product and classification
K260396 covers a repetitive transcranial magnetic stimulation system classified under 21 CFR 882.5805, device class 2, product code OBP, with neurology as the medical specialty and review panel. FDA product classification material for OBP describes the device type as a transcranial magnetic stimulator that delivers brief-duration, rapidly alternating or pulsed magnetic fields to induce electrical currents, with the cerebral cortex listed as the target area. The FDA decision letter names the trade device as the KCS rTMS Therapy System (Transcranial Magnetic Stimulator) (MetaStim 100, MetaStim 100A). [1][2][5][8]
Submission dates and review path
The FDA record shows a date received of February 6, 2026 and a decision date of September 6, 2026, with decision code SESE and decision description Substantially Equivalent. The clearance type is Traditional and the third-party flag is N, indicating the submission was not reviewed under the third-party review pathway. The advisory committee and review advisory committee are both listed as NE, Neurology. The submission is recorded as including a Summary. [1][2][9]
The supplied collection contains one linked 510(k) record, and its decision count is one SESE. The record sample likewise contains that single entry, so the sample decision count of one SESE matches the full supplied collection rather than a smaller subset. These figures describe the supplied filings only and do not represent total company sales, total portfolio or safety performance. [1][9]
Components described in the review file
The review document excerpt lists coil parameters for several configurations, including MD-60 with a 50 mm inner diameter, 81 mm outer diameter, and a winding described as 2 wings by 4 layers by 3 turns; BY90A with a 34 mm inner diameter and 85 mm outer diameter; and FEC-02-100-C with inner dimensions of 47 by 50 mm and outer dimensions of 97 by 100 mm. Cooling descriptions in the same excerpt include forced air for BF90A, liquid cooling for BY90B, and liquid cooling for FEC-02-100-C and AFEC-02-100-C, with FEC-02-100 and AFEC-02-100 listed as optional accessories with no cooling specified. The excerpt marks these coil parameters as similar to a predicate. [2]
Applicant identity and regulatory context
Fidelity BioPharma Co. is identified as the applicant in the FDA 510(k) database entry and in the decision letter, which is routed through Cassie Lee, Manager, Guangzhou Medical Consultant, Ltd., at an address in Guangzhou, China. The filing address and consultant address are correspondence details in the FDA record and do not establish a corporate headquarters. No parent company, brand ownership, website, customer list or commercial availability is verified in the public documents. FDA guidance for rTMS systems, issued July 26, 2011, sets out Class II special controls for this device category, and the guidance notes that final labeling must comply with 21 CFR Part 801 and, for prescription devices, 21 CFR 801.109. [1][2][6][7]

